

What is claimed is:

1. An ophthalmic composition, comprising Indigo Carmine.
2. The ophthalmic composition of claim 1, wherein the ophthalmic composition is an aqueous composition.
3. The ophthalmic composition of claim 1 or claim 2, wherein the Indigo Carmine is present in an amount in the range of between approximately 0.001-0.4 wt.%, relative to the ophthalmic composition.
4. The ophthalmic composition of any one of claims 1-3, wherein the Indigo Carmine is present in an amount in the range of between approximately 0.001-0.3 wt.%, between approximately 0.001-0.2 wt.%, between approximately 0.001-0.1 wt.%, between approximately 0.001-0.05 wt.%, between approximately 0.001-0.01 wt.%, between approximately 0.004-0.4 wt.%, between approximately 0.004-0.04 wt.%, between approximately 0.005-0.4 wt.%, between approximately 0.005-0.3 wt.%, between approximately 0.005-0.2 wt.%, between approximately 0.005-0.1 wt.%, between approximately 0.005-0.05 wt.%, between approximately 0.005-0.01 wt.%, between approximately 0.01-0.35 wt.%, between approximately 0.01-0.3 wt.%, between approximately 0.01-0.25 wt.%, between approximately 0.01-0.2 wt.%, between approximately 0.01-0.15 wt.%, between approximately 0.01-0.1 wt.%, between approximately 0.04-0.4 wt.%, between approximately 0.05-0.4 wt.%, between

approximately 0.1-0.4 wt.%, between approximately 0.15-0.4 wt.%, between approximately 0.2-0.4 wt.%, between approximately 0.25-0.4 wt.%, between approximately 0.3-0.4 wt.%, between approximately 0.35-0.4 wt.%, between approximately 0.1-0.3 wt.%, between approximately 0.1-0.2 wt.%, between approximately 0.01-0.05 wt.%, or between approximately 0.05-0.1 wt.%, relative to the ophthalmic composition.

5. The ophthalmic composition of any one of claims 1-4, wherein the Indigo Carmine is present in an amount of approximately 0.001 wt.%, approximately 0.002 wt.%, approximately 0.003 wt.%, approximately 0.004 wt.%, approximately 0.005 wt.%, approximately 0.006 wt.%, approximately 0.007 wt.%, approximately 0.008 wt.%, approximately 0.009 wt.%, approximately 0.01 wt.%, approximately 0.02 wt.%, approximately 0.03 wt.%, approximately 0.04 wt.%, approximately 0.05 wt.%, approximately 0.06 wt.%, approximately 0.07 wt.%, approximately 0.08 wt.%, approximately 0.09 wt.%, approximately 0.1 wt.%, approximately 0.2 wt.%, approximately 0.3 wt.%, or approximately 0.4 wt.%, relative to the ophthalmic composition.

6. The ophthalmic composition of any one of claims 1-5, wherein the Indigo Carmine is present in an amount of at least 0.001 wt.%, at least 0.002 wt.%, at least 0.003 wt.%, at least 0.004 wt.%, at least 0.005 wt.%, at least 0.006 wt.%, at least 0.007 wt.%, at least 0.008 wt.%, at least 0.009 wt.%, at least 0.01 wt.%, at least 0.02 wt.%, at least 0.03 wt.%, at least 0.04 wt.%, at least 0.05 wt.%, at least 0.06 wt.%, at least 0.07 wt.%, at least

0.08 wt.%, at least 0.09 wt.%, at least 0.1 wt.%, at least 0.15 wt.%, at least 0.2 wt.%, at least 0.25 wt.%, at least 0.3 wt.%, or at least 0.35 wt.%, relative to the ophthalmic composition.

7. The ophthalmic composition of any one of claims 1-6, wherein the ophthalmic composition further comprises Trypan Blue.

8. The ophthalmic composition of any one of claims 1-7, wherein the Trypan Blue is present in an amount in the range of between approximately 0.001-0.1 wt.%, relative to the ophthalmic composition.

9. The ophthalmic composition of any one of claims 1-8, wherein the Trypan Blue is present in an amount less than 0.1 wt.%, relative to the ophthalmic composition.

10. The ophthalmic composition of any one of claims 1-9, wherein the Trypan Blue is present in an amount less than 0.05 wt.%, less than 0.04 wt.%, less than 0.03 wt.%, less than 0.02 wt.%, or less than 0.01 wt.%, relative to the ophthalmic composition.

11. The ophthalmic composition of any one of claims 1-10, wherein the Trypan Blue is present in an amount in the range of between approximately 0.001-0.1 wt.%, between approximately 0.001-0.05 wt.%, approximately 0.001-0.045 wt.%, approximately 0.001-0.04 wt.%, between approximately 0.001-0.035 wt.%, between approximately 0.001-0.03 wt.%, between approximately 0.001-0.025 wt.%, between approximately 0.001-0.02

wt.%, between approximately 0.001-0.015 wt.%, between approximately 0.001-0.01 wt.%, between approximately 0.005-0.1 wt.%, between approximately 0.005-0.05 wt.%, between approximately 0.005-0.045 wt.%, between approximately 0.005-0.04 wt.%, between approximately 0.005-0.035 wt.%, between approximately 0.005-0.03 wt.%, between approximately 0.005-0.025 wt.%, between approximately 0.005-0.02 wt.%, between approximately 0.005-0.015 wt.%, between approximately 0.005-0.01 wt.%, between approximately 0.01-0.1 wt.%, between approximately 0.01-0.05 wt.%, between approximately 0.01-0.045 wt.%, between approximately 0.01-0.04 wt.%, between approximately 0.01-0.035 wt.%, between approximately 0.01-0.03 wt.%, between approximately 0.01-0.025 wt.%, between approximately 0.01-0.02 wt.%, between approximately 0.01-0.015 wt.%, or between approximately 0.02-0.04 wt.%, relative to the ophthalmic composition.

12. The ophthalmic composition of any one of claims 1-11, wherein the Trypan Blue is present in an amount of approximately 0.001 wt.%, approximately 0.005 wt.%, approximately 0.01 wt.%, approximately 0.015 wt.%, approximately 0.02 wt.%, approximately 0.025 wt.%, approximately 0.03 wt.%, approximately 0.035 wt.%, approximately 0.04 wt.%, approximately 0.045 wt.%, approximately 0.05 wt.%, or approximately 0.1 wt.%, relative to the ophthalmic composition.

13. The ophthalmic composition of any one of claims 1-12, wherein the ophthalmic composition further comprises Brilliant Blue.

14. The ophthalmic composition of any one of claims 1-13, wherein the ophthalmic composition further comprises Patent Blue.

15. The ophthalmic composition of any one of claims 1-14, wherein the ophthalmic composition further comprises Indocyanine Green.

16. The ophthalmic composition of any one of claims 1-15, wherein the ophthalmic composition further comprises Fluorescein.

17. The ophthalmic composition of any one of claims 1-16, wherein the ophthalmic composition is an injectable ophthalmic formulation.

18. The ophthalmic composition of any one of claims 1-17, wherein the ophthalmic composition further comprises one or more additional ophthalmically acceptable excipients and additives.

19. The ophthalmic composition of any one of claims 1-18, wherein the ophthalmic composition comprises an ophthalmic irrigation solution.

20. The ophthalmic composition of any one of claims 1-19, wherein the ophthalmic composition is used for application to an eye.

21. The ophthalmic composition of claim 20, wherein the application of the ophthalmic composition to the eye is via topical application to said eye.
22. The ophthalmic composition of claim 20, wherein the application of the ophthalmic composition to the eye is via injection into said eye.
23. The ophthalmic composition of claim 20, wherein the application of the ophthalmic composition to the eye is via injection into the anterior chamber of said eye.
24. The ophthalmic composition of any one of claims 20-23, wherein the eye is a glaucomatous eye.
25. The ophthalmic composition of any one of claims 20-24, wherein the eye has a cataract.
26. A method for ocular surgery in a patient in need thereof, comprising instilling the ophthalmic composition of any one of claims 1-25 into the patient's eye.
27. A method for identifying an intraocular structure(s) or membrane(s) within an eye of a patient in need thereof, comprising instilling the ophthalmic composition of any one of claims 1-25 into the patient's eye.

28. A method for introducing an ophthalmic device into an eye of a patient in need thereof, comprising:

- i) instilling the ophthalmic composition of any one of claims 1-25 into the patient's eye; and
- ii) introducing the ophthalmic device into the instilled eye.

29. A method for identification of canal of Schlemm within an eye of a patient in need thereof, comprising instilling the ophthalmic composition of any one of claims 1-25 into the patient's eye.

30. A method of cataract extraction and treatment of glaucoma in an eye of a patient in need thereof, comprising:

- i) instilling a first ophthalmic composition comprising Trypan Blue into the patient's eye;
- ii) surgically extracting the cataract of the Trypan Blue instilled eye;
- iii) instilling a second ophthalmic composition into the cataract extracted eye, wherein the second ophthalmic composition is the ophthalmic composition of any one of claims 1-25; and
- iv) surgically treating the glaucoma of said cataract extracted eye.

31. A method of cataract extraction and treatment of glaucoma in an eye of a patient in need thereof, comprising:

- i) instilling the ophthalmic composition of any one of claims 1-25 into the patient's eye;
- ii) surgically extracting the cataract of the instilled eye; and
- iii) surgically treating the glaucoma of the cataract extracted eye.

32. The method of any one of claims 26-31, wherein the method includes an ocular surgery, or the ocular surgery is, selected from the group consisting of: glaucoma surgery, minimally invasive glaucoma surgery (MIGS), cataract surgery, retinal surgery, lens replacement surgery, surgery to treat ocular trauma, refractive lensectomy, corneal surgery, endothelial keratoplasty, Descemet's Membrane Endothelial Keratoplasty (DMEK), capsulorhexis, lamellar corneal transplantation, minimally invasive corneal procedure, corneal refractive procedure, small incision lenticule extraction (SMILE), Ab interno Canaloplasty (ABiC), Ab externo Canaloplasty (ABeC), retinal procedures such as removal of epiretinal membranes, and ocular surface diagnostic technique.

33. The method of any one of claims 26-32, wherein the method, or the ocular surgery, includes a combination of two or more of the following ocular surgeries selected from the group consisting of: glaucoma surgery, minimally invasive glaucoma surgery (MIGS), cataract surgery, retinal surgery, lens replacement surgery, surgery to treat ocular trauma, refractive lensectomy, corneal surgery, endothelial keratoplasty, Descemet's Membrane Endothelial Keratoplasty (DMEK), capsulorhexis, lamellar corneal transplantation, minimally invasive corneal procedure, corneal refractive procedure, small incision lenticule extraction (SMILE), Ab interno Canaloplasty (ABiC),

Ab externo Canaloplasty (ABeC), retinal procedures such as removal of epiretinal membranes, and ocular surface diagnostic technique.

34. The method of any one of claims 26-33, wherein the ocular surgery is or includes glaucoma surgery.

35. The method of any one of claims 26-34, wherein the ocular surgery is or includes minimally invasive glaucoma surgery (MIGS).

36. The method of any one of claims 26-35, wherein the ocular surgery is or includes cataract surgery.

37. The method of any one of claims 26-36, wherein the ocular surgery is or includes retinal surgery.

38. The method of any one of claims 26-37, wherein the ocular surgery is or includes lens replacement surgery.

39. The method of any one of claims 26-38, wherein the ocular surgery is or includes surgery to treat ocular trauma.

40. The method of any one of claims 26-39, wherein the ocular surgery is or includes refractive lensectomy.

41. The method of any one of claims 26-40, wherein the ocular surgery is or includes corneal surgery.
42. The method of any one of claims 26-41, wherein the ocular surgery comprises extracting a cataract and treating glaucoma.
43. The method of any one of claims 26-42, wherein the ocular surgery is or includes endothelial keratoplasty.
44. The method of any one of claims 26-43, wherein the ocular surgery is or includes Descemet's Membrane Endothelial Keratoplasty (DMEK).
45. The method of any one of claims 26-44, wherein the ocular surgery is or includes capsulorhexis.
46. The method of any one of claims 26-45, wherein the ocular surgery is or includes lamellar corneal transplantation.
47. The method of any one of claims 26-46, wherein the ocular surgery is or includes a minimally invasive corneal procedure.

48. The method of any one of claims 26-47, wherein the ocular surgery is or includes a minimally invasive corneal procedure corrects refractive error.

49. The method of any one of claims 26-48, wherein the ocular surgery is or includes a corneal refractive procedure.

50. The method of any one of claims 26-49, wherein the ocular surgery is or includes a small incision lenticule extraction (SMILE).

51. The method of any one of claims 26-50, wherein the ocular surgery is or includes an Ab interno Canaloplasty (ABiC).

52. The method of any one of claims 26-51, wherein the ocular surgery is or includes an Ab externo Canaloplasty (ABeC).

53. The method of any one of claims 26-52, wherein the ocular surgery is or includes an ocular surface diagnostic technique.

54. The method of any one of claims 26-53, wherein the ocular surgery is a combination of glaucoma surgery and cataract surgery.

55. The method of any one of claims 26-54, wherein the ocular surgery is a combination of minimally invasive glaucoma surgery (MIGS) and cataract surgery.

56. The method of any one of claims 26-55, wherein the ocular surgery is a combination of minimally invasive glaucoma surgery (MIGS) and endothelial keratoplasty.

57. The method of any one of claims 26-56, wherein the ocular surgery is a combination of endothelial keratoplasty and cataract surgery.

58. The method of any one of claims 26-57, wherein the patient's eye is glaucomatous.

59. The method of any one of claims 26-58, wherein the patient's eye has a cataract.

60. The method of any one of claims 26-59, wherein the ophthalmic composition is instilled into the eye by injection.

61. The method of any one of claims 26-60, wherein the ophthalmic composition is instilled into the eye by injection into the anterior chamber of the eye.

62. The method of any one of claims 26-61, wherein the ophthalmic composition is instilled into the eye by a plurality of injections.

63. The method of any one of claims 26-62, wherein the ophthalmic composition is instilled into the eye by a plurality of injections into the anterior chamber of the eye.

64. The method of any one of claims 26-63, wherein the method identifies, marks, or stains an intraocular structure(s) or membrane(s) within the patient's eye in a visually identifiable manner.

65. The method of any one of claims 26-64, wherein the method identifies, marks, or stains an intraocular structure(s) or membrane(s) within the patient's eye in a visually identifiable manner easily visible by the naked eye of a surgeon.

66. The method of any one of claims 26-65, wherein the intraocular structure(s) or membrane(s) within the patient's eye is identified, marked, or stained, in a visually identifiable manner.

67. The method of any one of claims 26-66, wherein a plurality of intraocular structures or membranes within the eye are identified, marked, or stained, in a visually identifiable manner.

68. The method of any one of claims 26-67, wherein the method facilitates ready identification of the intraocular structure(s) or membrane(s) within the eye.

69. The method of any one of claims 26-68, wherein the method identifies, marks, or stains a portion of the intraocular structure(s) or membrane(s) within the patient's eye.

70. The method of any one of claims 26-69, wherein the method identifies, marks, or stains a plurality of the intraocular structures or membranes within the patient's eye.

71. The method of any one of claims 26-70, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is selected from a group consisting of: a fine vessel, an aqueous vein, an episcleral vein, a collector channel, a collector channel/aqueous/episcleral vein system, an aqueous drainage system, a conjunctival venous system, a deep scleral plexus, a deep scleral plexus visually identifiable once a conjunctiva is reflected away, a trabecular meshwork, a canal of Schlemm, a suprachoroidal space, a scleral spur, anterior capsule of a crystalline lens, cornea, lens capsule, a retinal membrane, a corneal endothelial membrane, and Descemet's membrane.

72. The method of any one of claims 26-71, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a fine vessel.

73. The method of any one of claims 26-72, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a fine vessel is in the conjunctiva adjacent to the limbus.

74. The method of any one of claims 26-73, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is an aqueous vein.

75. The method of any one of claims 26-74, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is an episcleral vein.

76. The method of any one of claims 26-75, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a collector channel.

77. The method of any one of claims 26-76, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a collector channel/aqueous/episcleral vein system.

78. The method of any one of claims 26-77, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is an aqueous drainage system of said eye.

79. The method of any one of claims 26-78, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is conventional drainage system of said eye.

80. The method of any one of claims 26-79, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a conjunctival venous system.

81. The method of any one of claims 26-80, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a deep scleral plexus.

82. The method of any one of claims 26-81, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a deep scleral plexus visually identifiable once the conjunctiva is reflected away.

83. The method of any one of claims 26-82, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a trabecular meshwork.

84. The method of any one of claims 26-83, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a posterior aspect of a trabecular meshwork.

85. The method of any one of claims 26-84, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a canal of Schlemm.

86. The method of any one of claims 26-85, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a suprachoroidal space.

87. The method of any one of claims 26-86, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a scleral spur.

88. The method of any one of claims 26-87, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is the anterior capsule of a crystalline lens.

89. The method of any one of claims 26-88, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a cornea.

90. The method of any one of claims 26-89, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a lens capsule.

91. The method of any one of claims 26-90, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a retinal membrane.

92. The method of any one of claims 26-91, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a corneal endothelial membrane.

93. The method of any one of claims 26-92, wherein the identified, marked, or stained intraocular structure(s) or membrane(s) within the patient's eye is a Descemet's membrane.

94. The method of any one of claims 26-93, wherein the Indigo Carmine of the ophthalmic composition identifies, marks, or stains a trabecular meshwork and a canal of Schlemm in the patient's eye.

95. The method of any one of claims 26-94, wherein the Indigo Carmine of the ophthalmic composition identifies, marks, or stains a canal of Schlemm more than a trabecular meshwork in the patient's eye.

96. The method of any one of claims 26-95, wherein the Indigo Carmine of the ophthalmic composition identifies, marks, or stains a trabecular meshwork less than a canal of Schlemm in the patient's eye.

97. The method of any one of claims 26-96, wherein the method facilitates diagnosis of the patient's eye.

98. The method of any one of claims 26-97, wherein the method facilitates diagnosis of the intraocular structure(s) or membrane(s) within the patient's eye.

99. The method of any one of claims 26-98, wherein the method facilitates an ocular surgeon's diagnosis of fluid flow and drainage of the patient's eye during the ocular surgery.

100. The method of any one of claims 26-99, wherein the method facilitates treatment of the patient's eye.

101. The method of any one of claims 26-100, wherein the method facilitates surgical treatment of the patient's eye.

102. The method of any one of claims 26-101, wherein the method facilitates surgical treatment of the identified intraocular structure(s) or membrane(s) within the eye.

103. The method of any one of claims 26-102, wherein the method facilitates surgical removal of the identified intraocular structure(s) or membrane(s) within the eye.

104. The method of any one of claims 26-103, wherein the method facilitates extracting a cataract and treating glaucoma.

105. The method of any one of claims 26-104, wherein the method further comprises introducing an ophthalmic device into the instilled eye.

106. The method of any one of claims 26-105, wherein the instilled ophthalmic composition facilitates accurate and/or precise inserting, placement, positioning, repositioning, lifting, and/or removal, of an ophthalmic device within the patient's eye.

107. The method of any one of claims 26-106, wherein the method facilitates accurate and/or precise inserting, placement, positioning, repositioning, lifting, and/or removal, of an ophthalmic device proximate the identified intraocular structure(s) or membrane(s) within the patient's eye.

108. The method of any one of claims 26-107, wherein the method facilitates accurate and/or precise inserting, placement, positioning, repositioning, lifting, and/or removal, of a plurality of ophthalmic devices within the Indigo Carmine instilled patient's eye.

109. The method of any one of claims 26-108, wherein the method facilitates accurate and/or precise inserting of an ophthalmic device proximate the identified intraocular structure(s) or membrane(s) within the patient's eye.

110. The method of any one of claims 26-109, wherein the method facilitates accurate and/or precise placement of an ophthalmic device proximate the identified intraocular structure(s) or membrane(s) within the patient's eye.

111. The method of any one of claims 26-110, wherein the method facilitates accurate and/or precise positioning of an ophthalmic device proximate the identified intraocular structure(s) or membrane(s) within the patient's eye.

112. The method of any one of claims 26-111, wherein the method facilitates accurate and/or precise repositioning of an ophthalmic device proximate the identified intraocular structure(s) or membrane(s) within the patient's eye.

113. The method of any one of claims 26-112, wherein the method facilitates accurate and/or precise removal of an ophthalmic device proximate the identified intraocular structure(s) or membrane(s) within the patient's eye.

114. The method of any one of claims 26-113, wherein the ophthalmic device is a stent.

115. The method of any one of claims 26-114, wherein the method facilitates an ocular surgeon's determination of the type of stent to utilize during the ocular surgery.

116. The method of any one of claims 26-115, wherein the method facilitates an ocular surgeon's placement of the stent during the ocular surgery.

117. The method of any one of claims 26-116, wherein the method facilitates an ocular surgeon's determination of the type of stent to utilize and the placement of the stent during the ocular surgery.

118. The method of any one of claims 26-117, wherein the ophthalmic device is a glaucoma stent.

119. The method of any one of claims 26-118, wherein the ophthalmic device is a suprachoroidal stent.

120. The method of any one of claims 26-119, wherein the ophthalmic device is an intraocular lens during cataract surgery.

121. The method of any one of claims 26-120, wherein the ophthalmic device is introduced proximate to canal of Schlemm of the patient's eye.

122. The method of any one of claims 26-121, wherein the ophthalmic device is inserted into the canal of Schlemm of the patient's eye.

123. The method of any one of claims 26-122, wherein the ophthalmic device is inserted into the suprachoroidal space of the patient's eye.

124. The method of any one of claims 26-123, wherein the ophthalmic device is pre-treated with Indigo Carmine.

125. The method of any one of claims 26-124, wherein the ophthalmic device is pre-treated with Trypan Blue.

126. The method of any one of claims 26-125, wherein the method further comprises instilling an ophthalmic composition comprising Trypan Blue.

127. The method of any one of claims 26-126, wherein the instilled the ophthalmic composition comprises both Indigo Carmine and Trypan Blue.

128. The method of any one of claims 26-127, wherein intraocular structures or membranes of the instilled eye are identified, marked, or stained, by Indigo Carmine prior to extracting of the cataract.

129. The method of any one of claims 26-128, wherein intraocular structures or membranes of the instilled eye are identified, marked, or stained, by both Indigo Carmine and Trypan Blue prior to extracting of the cataract.

130. The method of any one of claims 26-129, wherein the surgical treatment of the glaucoma in said Indigo Carmine instilled eye comprises introducing an ophthalmic device into said eye.

131. The method of any one of claims 26-130, wherein the surgical treatment of the glaucoma in said Indigo Carmine instilled eye comprises:

- a) visually identifying an Indigo Carmine stained canal of Schlemm; and
- b) introducing an ophthalmic device into the patient's eye proximate the Indigo Carmine stained canal of Schlemm.

132. The method of any one of claims 26-131, wherein the Indigo Carmine containing ophthalmic composition and the Trypan Blue containing ophthalmic composition are co-instilled concurrently, co-instilled sequentially with instilling of the Indigo Carmine containing ophthalmic composition followed by the Trypan Blue containing ophthalmic composition, or co-instilled sequentially with instilling of the Trypan Blue containing ophthalmic composition followed by the Indigo Carmine containing ophthalmic composition.

133. The method of any one of claims 26-132, wherein the ophthalmic composition is instilled into the patient's eye over a period of time in the range of between 1 second to 2 minutes.

134. The method of any one of claims 26-133, wherein the ophthalmic composition is instilled into the patient's eye over a period of at least 10 seconds, at least 20 seconds, at least 30 seconds, at least 45 seconds, at least 1 minute, or at least 1.5 minutes.

135. The method of any one of claims 26-134, wherein the ophthalmic composition is instilled into the patient's eye over a period of time until the composition egresses from one or more channels in the patient's eye.

136. The method of any one of claims 26-135, wherein a plurality of instillations of the ophthalmic composition is conducted over a period of time until at least 25%, at least 50%, at least 75%, at least 90%, or at least 95%, of the canal of Schlemm is visually identifiable.

137. The method of any one of claims 26-136, wherein the method results in reduced surgical manipulation, relative to an ocular surgery not using said ophthalmic composition

138. The method of any one of claims 26-137, wherein the method results in reduced tissue manipulation, relative to an ocular surgery not using said ophthalmic composition

139. The method of any one of claims 26-138, wherein the method results in less severe adverse side effects, relative to an ocular surgery not using said ophthalmic composition